Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, RNAi etc. |
| Sample | CRC tissues, cell lines (HT29 and RKO) |
| Expression Pattern | up-regulated |
| Function Description | The CRC tissues were revealed to express higher levels of ANRIL lncRNA compared with the adjacent non-neoplastic tissues. Furthermore, high ANRIL expression was significantly associated with reduced survival rate. ANRIL gene expression was successfully silenced in human CRC cells. ANRIL knockdown decreased proliferation, inhibited migration and invasion, and reduced the colony-forming ability of the cells. |
| Pubmed ID | 27314206 |
| Year | 2016 |
| Title | ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro. |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |